Portola Pharmaceuticals Inc (PTLA) : Marcus Capital scooped up 2,125 additional shares in Portola Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 19, 2016. The investment management firm now holds a total of 75,150 shares of Portola Pharmaceuticals Inc which is valued at $1,774,292.Portola Pharmaceuticals Inc makes up approximately 1.78% of Marcus Capital’s portfolio.
Other Hedge Funds, Including , Eagle Asset Management Inc reduced its stake in PTLA by selling 218,228 shares or 31.13% in the most recent quarter. The Hedge Fund company now holds 482,719 shares of PTLA which is valued at $11,396,996. Portola Pharmaceuticals Inc makes up approx 0.08% of Eagle Asset Management Inc’s portfolio.Fox Run Management L.l.c. reduced its stake in PTLA by selling 5,800 shares or 21.64% in the most recent quarter. The Hedge Fund company now holds 21,000 shares of PTLA which is valued at $495,810. Portola Pharmaceuticals Inc makes up approx 0.23% of Fox Run Management L.l.c.’s portfolio. First Manhattan Co sold out all of its stake in PTLA during the most recent quarter. The investment firm sold 230,300 shares of PTLA which is valued $5,243,931.Fisher Asset Management boosted its stake in PTLA in the latest quarter, The investment management firm added 2,437 additional shares and now holds a total of 82,737 shares of Portola Pharmaceuticals Inc which is valued at $1,873,993.Cutler Group Lp boosted its stake in PTLA in the latest quarter, The investment management firm added 734 additional shares and now holds a total of 5,635 shares of Portola Pharmaceuticals Inc which is valued at $127,633. Portola Pharmaceuticals Inc makes up approx 0.01% of Cutler Group Lp’s portfolio.
Portola Pharmaceuticals Inc opened for trading at $22.91 and hit $23.73 on the upside on Wednesday, eventually ending the session at $23.61, with a gain of 5.17% or 1.16 points. The heightened volatility saw the trading volume jump to 6,79,959 shares. Company has a market cap of $1,333 M.
On the company’s financial health, Portola Pharmaceuticals Inc reported $-1.15 EPS for the quarter, missing the analyst consensus estimate by $ -0.18 based on the information available during the earnings call on May 5, 2016. Analyst had a consensus of $-0.97. The company had revenue of $8.30 million for the quarter, compared to analysts expectations of $7.91 million. The company’s revenue was up 245.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.95 EPS.
Many Wall Street Analysts have commented on Portola Pharmaceuticals Inc. Shares were Downgraded by Credit Suisse on May 31, 2016 to ” Neutral” and Lowered the Price Target to $ 30 from a previous price target of $33 .
Portola Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Companys two lead programs Betrixaban and Andexanet alfa address unmet medical needs in the area of thrombosis or blood clots. Its third product candidate is Cerdulatinib. The Company has a program of selective Syk inhibitors which is partnered with Biogen Idec Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa. Andexanet alfa is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor. Cerdulatinib is an orally available potent dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor.